Risk factors for bone mineral density loss in pediatric renal transplant patients
E N Ellis1, D M Floyd-Gimon, P L Berry
1Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock 72202, USA. EllisEileenN@exchange.UAMS.edu
Insights
Pediatric renal transplant recipients often experience decreased bone mineral density (BMD). Key risk factors include adolescence, longer time post-transplant, and corticosteroid use, necessitating further research and intervention strategies.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Bone mineral density (BMD) is reduced in pediatric renal transplant recipients.
- Understanding risk factors for BMD loss is crucial for long-term patient health.
Purpose of the Study:
- To identify risk factors associated with decreased BMD in children and adolescents following renal transplantation.
Main Methods:
- Dual-energy X-ray absorptiometry (DEXA) was used to assess BMD in 33 pediatric patients (aged 7-22 years).
- Data collected included age, weight, Tanner stage, dialysis history, and medication dosages (corticosteroids, cyclosporin A).
Main Results:
- A significant percentage of patients exhibited low BMD Z-scores (45% spine, 42% femur).
- Decreased BMD correlated inversely with increasing age, time post-transplant, and advanced Tanner stages (pubertal development).
- Cumulative corticosteroid dose was linked to lower total body BMD; ethnicity also played a role.
Conclusions:
- BMD deficits in pediatric renal transplant patients emerge during adolescence.
- Risk factors for BMD loss include age, time since transplant, pubertal stage, and ethnicity.
- Longitudinal studies and therapeutic strategies are recommended to improve BMD in this population.
Abstract:
Bone mineral density (BMD) is decreased in both adult and pediatric renal transplant recipients. To investigate the risk factors associated with this decrease in BMD post-renal transplant, we studied 33 children, aged 7-22 yr, who had received a renal transplant from 0.3 to 10 yr prior to this study. BMD analysis of the total body, spine, and femur was carried out by using dual-energy X-ray absorptiometry (DEXA). Age, weight, Tanner stage, time on dialysis prior to transplantation, cumulative corticosteroid dosage, and cyclosporin A (CsA) dosage since transplantation, and use of corticosteroid therapy prior to transplantation, were recorded. Spine, femur, and total body BMD Z-scores were greater than two standard deviations (2 SD) below the mean in 45%, 42%, and 17% of patients, respectively. Age correlated inversely with total body and spine BMD Z-scores (p = 0.001 and p = 0.008); no child under 14 yr of age had a total body or spine BMD Z-score greater than 2 SD below the mean for age. Patients at a Tanner stage of 4 or 5 had lower total body and spine BMD Z-scores than did patients at Tanner stages 1-3 (p = 0.043). Time post-transplant correlated inversely with both spine and total body BMD Z-score (p = 0.013 and p = 0.023). Only total body BMD Z-score correlated inversely with cumulative corticosteroid dose (in g, p = 0.045). BMD did not correlate with cumulative CsA dose. Black patients tended to have decreased total body BMD compared with Caucasian patients. In pediatric renal transplant patients, decreases in BMD start in adolescence. Risk factors for BMD loss in these patients include increasing age, time post-transplant, increasing Tanner stage, and ethnicity. Longitudinal studies in these patients and strategies to improve BMD are needed.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations


